Study Details
Full Title
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)
Principal Investigator
Jennifer
McNally
Protocol Number
PRO00119793
NCT ID
NCT07318558
Phase
III
Enrollment Status
Open to Enrollment